Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Telix Pharmaceuticals Ltd. securities during the specified Class Period, highlighting potential misstatements and misleading information from the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Telix Pharmaceuticals Ltd. securities purchased between February 21, 2025, and August 28, 2025 [1]. - The lawsuit alleges that defendants made materially false and misleading statements regarding the progress of Telix's prostate cancer therapeutic candidates and the quality of its supply chain [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by January 9, 2026, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].